A discussion of human trials of rapamycin and a walk-through of 2025 studies specifically.
- The PEARL trial: the first major human data on weekly low-dose rapamycin
- Early cardiovascular benefits at low doses
- Emerging research on long COVID and chronic fatigue
- The mTOR pathway, explained simply
- What animal studies (ITP) show vs. what we’re now seeing in humans
- Dosing and bioavailability: why more isn’t always better
- A year of safety data, explained
- Trials to watch in 2026 and 2027